Trima Non-DEHP Leukoreduced Red Blood Cell In Vivo Recovery Study

In Vivo 24-Hour Recovery Study of Leukoreduced RBCs Collected on the Trima Accel System Using Non-DEHP Disposable Sets and Stored for 42 Days

This is an in vivo 24-hour in-vivo recovery study of leukoreduced red blood cells (RBCs) collected on the Trima Accel System using Non-DEHP disposable sets and stored for 42 days.

Study Overview

• Status: Completed
• Conditions: Device Validation of In-vivo Performance
• Intervention / Treatment: Device: Trima Accel Auto RBC Collection

• Study Type: Interventional
• Enrollment (Actual): 37
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cincinnati, Ohio, United States, 45267
      • Hoxworth Blood Center, University of Cincinnati College of Medicine
  • Virginia
    • Norfolk, Virginia, United States, 23510
      • American Red Cross, Norfolk Clinical Research Lab

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Given written informed consent.
2. Age 18 years or older.
3. Normal health status as per AABB criteria for healthy donor.
4. Able to commit to the study schedule.

5. Meets the inclusion criteria defined by site SOPs for automated blood component collection systems or whole blood donation. These criteria are based on AABB standards and FDA regulations.

   a. Note: Participants who are deferred from volunteer community donations due to certain restrictions may participate in the study, as products are not used for allogeneic transfusion; however, sites may or may not implement this depending on their standard procedures.

6. Participants of childbearing potential (either male or female) must agree to use a medically acceptable method of contraception throughout the study.
7. Female participants of childbearing potential must agree to take a pregnancy test prior to the apheresis procedure and prior to reinfusion of radiolabeled LR-RBCs.
8. Participants must agree to report AEs throughout their participation in the study

Exclusion Criteria:

1. Currently pregnant or nursing females.
2. Serum ferritin less than12 ng/mL
3. Has previously completed this study with data included in the EAS.
4. Participation currently, or within the past 30 days, in another investigational trial that would potentially interfere with the analysis of this investigation (eg, pharmaceutical trial).

5. As determined by the Investigator:

   1. Has been diagnosed with a blood disorder(s) affecting RBC characteristics (eg, Glucose 6 Phosphate Dehydrogenase Deficiency [G6PD]),
   2. Reported history of RBC autoantibodies/autoimmune hemolytic anemia, RBC alloantibodies,
   3. Clinically significant acute or chronic disease, or
   4. Reported history of hypersensitivity to technetium or chromium
   5. Other unspecified reason that, in the opinion of the Investigator, makes the healthy adult volunteer unsuitable for enrollment.
6. Treatment with any medication as specified in site deferral list (based on AABB medication deferral list for apheresis donors).
7. Previously transfused/reinfused with RBCs within the last 120 days.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Healthy adult participants; Performance criteria will be evaluated in healthy adult participants, who receive radiolabeled, autologous infusions of LR-RBC components after being stored for 42 days at 2-6°C.	Device: Trima Accel Auto RBC Collection; This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from Trima Accel Auto RBC collection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Success of RBCs in Vivo Recovery After 42-day Storage (Single-label Method)	The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags. The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.; A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants; A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2); A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)	43 days
Number of Participants With Success of RBCs in Vivo Recovery After 42-day Storage (Dual-label Method)	The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags. The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.; A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants; A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2); A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)	43 days
Mean 24-hour, Post-transfusion, in Vivo RBC Recovery Percentage After 42-day Storage (Single-label Method)	The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags. The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.; A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants; A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2); A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)	43 days
Mean 24-hour, Post-transfusion, in Vivo RBC Recovery Percentage After 42-day Storage (Dual-label Method)	The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags. The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.; A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants; A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2); A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)	43 days

Collaborators and Investigators

• Sponsor: Terumo BCT

Study record dates

Study Major Dates

• Study Start (Actual): August 26, 2024
• Primary Completion (Actual): January 31, 2025
• Study Completion (Actual): January 31, 2025

Study Registration Dates

• First Submitted: September 16, 2024
• First Submitted That Met QC Criteria: September 16, 2024
• First Posted (Actual): September 19, 2024

Study Record Updates

• Last Update Posted (Actual): February 17, 2026
• Last Update Submitted That Met QC Criteria: January 29, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Red Blood Cell; RBC; Trima; Trima Accel System; Trima Non-DEHP Disposable Sets; Non-DEHP Disposable Sets; di(2-ethylhexyl) phthalate; Non-DEHP; Auto RBC; 24-hour red blood cell recovery; Investigational Non-DEHP Disposable Tubing Sets
• Other Study ID Numbers: CTS-5091

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Privacy concerns

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No